Merck Animal Health Partners with the American Association of Bovine Practitioners Foundation to Award $90,000 in Scholarships to Nine Promising Bovine Veterinary Students

The 2025 scholars were honored at the recent AABP Annual Conference

RAHWAY, N.J., Sept. 17, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it has awarded $90,000 in scholarships to nine future bovine veterinarians in partnership with the American Association of Bovine Practitioners (AABP) Foundation. Recipients of the Merck Animal Health Bovine Veterinary Student Recognition Award were selected based on their academic achievements, career goals, work experience and interest in veterinary medicine.

          The scholarships were recently awarded at the 2025 AABP Annual Conference, held Sept. 12-14 in Omaha, Neb. The 2025 scholarship recipients, each receiving $10,000, include:

• Brian Birkenhagen, University of Calgary Faculty of Veterinary Medicine, Class of 2026
• Thomas Christensen, Kansas State University College of Veterinary Medicine, Class of 2026
• Kaden Eisenbraun, University of Minnesota College of Veterinary Medicine, Class of 2027
• Matthew Holton, University of Georgia College of Veterinary Medicine, Class of 2026
• Chance March, Washington State University College of Veterinary Medicine, Class of 2026
• Eliza Merges, University of Minnesota College of Veterinary Medicine, Class of 2026
• Kagan Migl, Texas Tech University School of Veterinary Medicine, Class of 2027
• Maggie Taylor Moe, Texas Tech University School of Veterinary Medicine, Class of 2026
• Aaron (Gus) Peterson, Iowa State University College of Veterinary Medicine, Class of 2026

           “Merck Animal Health is proud to support the next generation of veterinary professionals who are passionate about advancing animal health and welfare,” said Dave Sjeklocha, D.V.M., technical services manager at Merck Animal Health and president of the AABP Board of Directors. “These scholarships recognize exceptional students who demonstrate the dedication and potential to make a meaningful impact in the veterinary profession.”

           “The partnership between Merck Animal Health and the AABP Foundation is vital in fostering the growth of future leaders in bovine practice,” said Fred Gingrich II, D.V.M., executive director of AABP. “We congratulate this year’s scholars and look forward to their contributions to the veterinary profession and the cattle industry in the years to come.”

          Founded in 1965, AABP is an international association of more than 5,000 veterinarians and veterinary students who serve as leaders in cattle health, welfare and productivity. To learn more, visit aabp.org.

The 2025 Merck Animal Health Bovine Student Recognition Award winners received $10,000 each at the 2025 American Association of Bovine Practitioners 58^th Annual Conference in Omaha, Neb., Sept. 11-13.

L-R: Dr. Lowell Midla; Kaden Eisenbraun, University of Minnesota; Gus (Aaron) Peterson, Iowa State University; Matt Holton, University of Georgia; Thomas Christensen II, Kansas State University; Brian Birkenhagen, University of Calgary; Kagan Migl, Texas Tech University; AABP President Dr. Dave Sjeklocha of Merck Animal Health.

Not pictured: Eliza Merges, University of Minnesota; Maggie Moe, Texas Tech University; Chance Marsh, Washington State University

About Merck Animal Health

          At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals^®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

          This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

          Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023, and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).